【參考文獻】
- Chao TF, Lip GY, Liu CJ, Tuan TC, Chen SJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Chen TJ, Chiang CE, Chen SA. Validation of a Modified CHA2DS2-VASc Score for Stroke Risk Stratification in Asian Patients With Atrial Fibrillation A Nationwide Cohort Study. Stroke. 2016; 47(10):2462-2469
- Chan YH, See LC, Tu HT, et al. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2018;7(8):e008150.
- Drug - nutrition interactions:Coumadin and vitamin K. Warren Grant Magnuson Clinical Center, National Institutes of Health.
- 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary. Journal of the American College of Cardiology, 64(21).
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016; 37:2893–2962.
- 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. Journal of the Formosan Medical Association.2016; 115:893-952.
- Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral
anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383(9921):955-62.
【版本】2019年第二版,更新日期:2019.11.06
【經費來源】本工具由衛生福利部「醫病共享決策推廣計畫」項下經費支應。經費來源及研發團隊成員與此工具相關醫療選項沒有利益衝突、經濟利益或贊助關係。
【研發團隊】
2017年第一版: 王英偉、石崇良、李宜恭、林宏榮、侯文萱、柯文欽、洪崇烈、徐圭璋、翁文能、梁蕙雯、陳可欣、陳厚全、陳盈如、陳景寧、廖熏香、劉人瑋、譚家偉 (依姓名筆劃排序) 游育苓、吳碧娟、莊舒閔
2019年第二版: 李宜恭、林亮宇、侯文萱、紀景琪、陳可欣、陳祖裕、廖熏香、劉人瑋、劉建良、鄭浩民 (依姓名筆劃排序) 陳嘉珮、吳碧娟、許競允
出版日期:2019-11-06
更新日期:2019-11-06